Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin as Adjuvant Therapy for High-risk Locoregional Advanced Nasopharyngeal Carcinoma
NCT07303283Phase 2Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Aug 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in nasopharyngeal carcinoma (NPC) comparing Adjuvant Becotatug Vedotin with observation (2 arms). Primary endpoint: Event-Free Survival at 2 years. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07303283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07303283.